Ketalar (Page 3 of 3)

Supplementary Agents:

Ketalar is clinically compatible with the commonly used general and local anesthetic agents when an adequate respiratory exchange is maintained.

The regimen of a reduced dose of Ketalar supplemented with diazepam can be used to produce balanced anesthesia by combination with other agents such as nitrous oxide and oxygen.

HOW SUPPLIED

Ketalar is supplied as the hydrochloride in concentrations equivalent to ketamine base.
NDC 42023-113-10 — Each 20-mL multi-dose vial contains 10 mg/mL. Supplied in cartons of 10.
NDC 42023-114-10 — Each 10-mL multi-dose vial contains 50 mg/mL. Supplied in cartons of 10.
NDC 42023-115-10 — Each 5-mL multi-dose vial contains 100 mg/mL. Supplied in cartons of 10.

Store between 20° to 25°C (68° to 77°F). (See USP controlled room temperature.)

Protect from light.

Rx only.

ANIMAL PHARMACOLOGY AND TOXICOLOGY

Toxicity:

The acute toxicity of Ketalar has been studied in several species. In mature mice and rats, the intraperitoneal LD50 values are approximately 100 times the average human intravenous dose and approximately 20 times the average human intramuscular dose. A slightly higher acute toxicity observed in neonatal rats was not sufficiently elevated to suggest an increased hazard when used in pediatric patients. Daily intravenous injections in rats of five times the average human intravenous dose and intramuscular injections in dogs at four times the average human intramuscular dose demonstrated excellent tolerance for as long as 6 weeks. Similarly, twice weekly anesthetic sessions of one, three, or six hours’ duration in monkeys over a four- to six-week period were well tolerated.

Interaction with Other Drugs Commonly Used for Preanesthetic Medication:

Large doses (three or more times the equivalent effective human dose) of morphine, meperidine, and atropine increased the depth and prolonged the duration of anesthesia produced by a standard anesthetizing dose of Ketalar in Rhesus monkeys. The prolonged duration was not of sufficient magnitude to contraindicate the use of these drugs for preanesthetic medication in human clinical trials.

Blood Pressure:

Blood pressure responses to Ketalar vary with the laboratory species and experimental conditions. Blood pressure is increased in normotensive and renal hypertensive rats with and without adrenalectomy and under pentobarbital anesthesia.

Intravenous Ketalar produces a fall in arterial blood pressure in the Rhesus monkey and a rise in arterial blood pressure in the dog. In this respect the dog mimics the cardiovascular effect observed in man. The pressor response to Ketalar injected into intact, unanesthetized dogs is accompanied by a tachycardia, rise in cardiac output and a fall in total peripheral resistance. It causes a fall in perfusion pressure following a large dose injected into an artificially perfused vascular bed (dog hindquarters), and it has little or no potentiating effect upon vasoconstriction responses of epinephrine or norepinephrine. The pressor response to Ketalar is reduced or blocked by chlorpromazine (central depressant and peripheral α-adrenergic blockade), by β-adrenergic blockade, and by ganglionic blockade. The tachycardia and increase in myocardial contractile force seen in intact animals does not appear in isolated hearts (Langendorff) at a concentration of 0.1 mg of Ketalar or in Starling dog heart-lung preparations at a Ketalar concentration of 50 mg/kg of HLP. These observations support the hypothesis that the hypertension produced by Ketalar is due to selective activation of central cardiac stimulating mechanisms leading to an increase in cardiac output. The dog myocardium is not sensitized to epinephrine and Ketalar appears to have a weak antiarrhythmic activity.

Metabolic Disposition:

Ketalar is rapidly absorbed following parenteral administration. Animal experiments indicated that Ketalar was rapidly distributed into body tissues, with relatively high concentrations appearing in body fat, liver, lung, and brain; lower concentrations were found in the heart, skeletal muscle, and blood plasma. Placental transfer of the drug was found to occur in pregnant dogs and monkeys. No significant degree of binding to serum albumin was found with Ketalar.

Balance studies in rats, dogs, and monkeys resulted in the recovery of 85% to 95% of the dose in the urine, mainly in the form of degradation products. Small amounts of drug were also excreted in the bile and feces. Balance studies with tritium-labeled Ketalar in human subjects (1 mg/lb given intravenously) resulted in the mean recovery of 91% of the dose in the urine and 3% in the feces. Peak plasma levels averaged about 0.75 µg/mL, and CSF levels were about 0.2 µg/mL, 1 hour after dosing.

Ketalar undergoes N-demethylation and hydroxylation of the cyclohexanone ring, with the formation of water-soluble conjugates which are excreted in the urine. Further oxidation also occurs with the formation of a cyclohexanone derivative. The unconjugated N-demethylated metabolite was found to be less than one-sixth as potent as Ketalar. The unconjugated demethyl cyclohexanone derivative was found to be less than one-tenth as potent as Ketalar. Repeated doses of Ketalar administered to animals did not produce any detectable increase in microsomal enzyme activity.

Reproduction:

Male and female rats, when given five times the average human intravenous dose of Ketalar for three consecutive days about one week before mating, had a reproductive performance equivalent to that of saline-injected controls. When given to pregnant rats and rabbits intramuscularly at twice the average human intramuscular dose during the respective periods of organogenesis, the litter characteristics were equivalent to those of saline-injected controls. A small group of rabbits was given a single large dose (six times the average human dose) of Ketalar on Day 6 of pregnancy to simulate the effect of an excessive clinical dose around the period of nidation. The outcome of pregnancy was equivalent in control and treated groups.

To determine the effect of Ketalar on the perinatal and postnatal period, pregnant rats were given twice the average human intramuscular dose during Days 18 to 21 of pregnancy. Litter characteristics at birth and through the weaning period were equivalent to those of the control animals. There was a slight increase in incidence of delayed parturition by one day in treated dams of this group. Three groups each of mated beagle bitches were given 2.5 times the average human intramuscular dose twice weekly for the three weeks of the first, second, and third trimesters of pregnancy, respectively, without the development of adverse effects in the pups.

Prescribing Information as of March 2012.

Manufactured and Distributed by:
JHP Pharmaceuticals, LLC
Rochester, MI 48307

3000442D

PRINCIPAL DISPLAY PANEL — 20 mL Vial Carton

NDC 42023-113-10

Ketalar ®
(Ketamine Hydrochloride Injection, USP)

CIII

200 mg per 20 mL*
(10 mg/mL)

Rx Only

10 VIALS (20 mL each)

JHP PHARMACEUTICALS

PRINCIPAL DISPLAY PANEL -- 20 mL Vial Carton
(click image for full-size original)

PRINCIPAL DISPLAY PANEL — 10 mL Vial Carton

NDC 42023-114-10

Ketalar ®
(Ketamine Hydrochloride Injection, USP)

CIII

500 mg per 10 mL*
(50 mg/mL)

Rx Only

10 VIALS (10 mL each)

JHP PHARMACEUTICALS

PRINCIPAL DISPLAY PANEL -- 10 mL Vial Carton
(click image for full-size original)

PRINCIPAL DISPLAY PANEL — 5 mL Vial Carton

NDC 42023-115-10

Ketalar ®
(Ketamine Hydrochloride Injection, USP)

CIII

CONCENTRATE
500 mg per 5 mL*
(100 mg/mL)

Rx Only

MUST BE DILUTED PRIOR TO IV USE

10 VIALS (5 mL each)

JHP PHARMACEUTICALS

PRINCIPAL DISPLAY PANEL -- 5 mL Vial Carton
(click image for full-size original)
KETALAR ketamine hydrochloride injection
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:42023-113
Route of Administration INTRAVENOUS, INTRAMUSCULAR DEA Schedule CIII
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
ketamine hydrochloride (ketamine) ketamine 10 mg in 1 mL
Inactive Ingredients
Ingredient Name Strength
benzethonium chloride
sodium chloride
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:42023-113-10 10 VIAL in 1 CARTON contains a VIAL
1 20 mL in 1 VIAL This package is contained within the CARTON (42023-113-10)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA016812 10/01/2007
KETALAR ketamine hydrochloride injection
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:42023-114
Route of Administration INTRAVENOUS, INTRAMUSCULAR DEA Schedule CIII
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
ketamine hydrochloride (ketamine) ketamine 50 mg in 1 mL
Inactive Ingredients
Ingredient Name Strength
benzethonium chloride
sodium chloride
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:42023-114-10 10 VIAL in 1 CARTON contains a VIAL
1 10 mL in 1 VIAL This package is contained within the CARTON (42023-114-10)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA016812 10/01/2007
KETALAR ketamine hydrochloride injection
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:42023-115
Route of Administration INTRAVENOUS, INTRAMUSCULAR DEA Schedule CIII
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
ketamine hydrochloride (ketamine) ketamine 100 mg in 1 mL
Inactive Ingredients
Ingredient Name Strength
benzethonium chloride
sodium chloride
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:42023-115-10 10 VIAL in 1 CARTON contains a VIAL
1 5 mL in 1 VIAL This package is contained within the CARTON (42023-115-10)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA016812 10/01/2007
Labeler — JHP Pharmaceuticals LLC (804894611)

Revised: 08/2013 JHP Pharmaceuticals LLC

Page 3 of 3 1 2 3

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.